Profile: Exelixis Inc (EXEL.O)
Exelixis, Inc., incorporated on November 15, 1994, is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. Its cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. Its CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs.
Cabozantinib inhibits the activity of tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors, MET, AXL and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes, such as oncogenesis, metastasis, tumor angiogenesis and maintenance of the tumor microenvironment.
Cobimetinib is a potent, selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. The Company is engaged in development and commercialization of Cobimetinib in collaboration with Genentech. COTELLIC is also approved in the European Union and Switzerland for the treatment of people with BRAF V600 mutation-positive advanced melanoma.
XL888 is an oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein. XL888 affects the activity and stability of a range of regulatory proteins, including kinases, such as BRAF, MET and vascular endothelial growth factor receptor 2 (VEGFR2), which are implicated in cancer cell proliferation and survival.
The Company has established collaborations with other pharmaceutical and biotechnology companies for various compounds and programs in its portfolio. The Company has collaborations with GlaxoSmithKline to discover and develop therapeutics in the areas of vascular biology, inflammatory disease and oncology. It has collaborations with Bristol-Myers Squibb for the discovery, development and commercialization of therapies targeted against LXR a nuclear hormone receptor implicated in cardiovascular and metabolic disorders. The Company has collaboration with Daiichi Sankyo for the discovery, development and commercialization of therapies targeted against the mineralocorticoid receptor a nuclear hormone receptor implicated in a range of cardiovascular and metabolic diseases.
The Company competes with Bayer, Amgen, Pfizer, Ariad Pharmaceutical, Novartis and Eisai.
210 E Grand Ave
SOUTH SAN FRANCISCO CA 94080-4811
Company Web Links
- BRIEF-Exelixis submits U.S. Supplemental New Drug Application for Cabometyx for the treatment of advanced kidney cancer
- BRIEF-Exelixis announces settlement of dispute with Genentech
- BRIEF-Exelixis, Bristol-Myers Squibb initiate phase 3 trial
- BRIEF-Ipsen and Exelixis announce IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib
- BRIEF-Exelixis announces Independent Radiology Committee review confirms results from CABOSUN